| Properties | Information |
|---|---|
| PhytoCAT-ID | PhytoCAT-1764 |
| Phytochemical name or plant extracts | Vinorelbine |
| PMID | 22122393 |
| Literature evidence | The antitumor activity of VNR is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. |
| IUPAC name | methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(12S,14R)-16-ethyl-12-methoxycarbonyl-1,10-diazatetracyclo[12.3.1.03,11.04,9]octadeca-3(11),4,6,8,15-pentaen-12-yl]-10-hydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate |
| Phytochemicals’ class or type of plant extracts | Alkaloid |
| Source of phytochemicals or plant Extracts | NA |
| Geographical availability | NA |
| Plant parts | NA |
| Other cancers | Breast cancer, Lung cancer |
| Target gene or protein | Caspase 3, Caspase 9, Caspase 8, cyt-c, Bid, HER2, Tp53, Bax, Bcl-2 mRNA , miR-222-3p |
| Gene or Protein evidence | Western blotting suggests that vinorelbine cleaves caspase-3, -9 and -8 and reduces the amount of mitochondrial cytochrome c. A downstream substrate for caspase-8, Bid, is also cleaved in vinorelbine-treated cells, but the Bid truncation is also observed in caspase-8-deficient Jurkat cells. A synergistic effect has been observed between vinorelbine and trastuzumab in patients with a hyperexpression of HER2 in their tumours. Treatment of BT-20 cells with vincristine, vinblastine, and/or vinorelbine resulted in upregulation of TP53 expression. On the other hand, treatment of SK-BR-3 cells with any of these vinca alkaloids led to an increase in the BAX/BCL2 mRNA ratio, implying the activation of the intrinsic apoptotic pathway. No concomitant alteration in TP53 expression was observed in treated SKBR- 3 cells. Regarding the miRNAs examined in this study, miR-222-3p expression exhibited the most remarkable modulations in both treated cell lines. |
| Target pathways | In this report, we demonstrate that VNB, as an antimicrotubule agent, induces apoptosis in breast cancer cell line, MX-1 via a mitochondrial pathway. |
| IC50 | NA |
| Potency | Vinorelbine is active in metastatic breast cancer with a first time response rate of 40% to 52%. High response rates were observed with combination chemotherapies of vinorelbine and other active agents for breast cancer. |
| Cell line/ mice model | MX-1, MCF-7 |
| Additional information | Vinorelbine is a chemotherapeutic vinca alkaloid clinically prescribed for non-small cell lung cancer and breast cancer. |
| PubChem ID | 5311497 |
| Additional PMIDs | 18297401 10945030 1893762 17431345 8995513 |
| Additional sources of information | NA |
| Safety | NA |